Close Menu
Peritoneo.life

    Subscribe to Our Newsletter

    Join our community of medical professionals and receive the latest expert insights, clinical updates, and breakthrough research on peritoneal surface malignancies.

    Latest Articles

    Understanding the GNAS Mutation in Pseudomyxoma Peritonei: Molecular Insights, Mucin Regulation, and Therapeutic Implications

    04/18/2025

    🔬 Immunotherapy in Pseudomyxoma Peritonei (PMP): Can We Overcome the Mucin Barrier?

    04/09/2025

    Understanding GNAS Mutations in Pseudomyxoma Peritonei: Molecular Insights and Clinical Implications

    04/09/2025
    Instagram YouTube
    Peritoneo.lifePeritoneo.life
    Instagram YouTube
    NEWSLETTER
    • Home
    • Disease
      1. CCR PSM
      2. DMPM PSM
      3. GAST PSM
      4. LAPHIPEC
      5. OVA PSM
      6. PIPAC
NIPS
      7. PMP PSM
      8. Technique:
HIPEC
      9. View All

      Circulating Tumor DNA in Colorectal Cancer | ASCO GI 2025 Insights

      04/01/2025

      Revolutionizing Peritoneal Cancer Treatment: Key Studies Unveiled at ASCO 2023

      03/06/2025

      🔬 CHIPOR Trial: Does HIPEC Improve Survival in Recurrent Ovarian Cancer?

      04/06/2025

      Understanding the GNAS Mutation in Pseudomyxoma Peritonei: Molecular Insights, Mucin Regulation, and Therapeutic Implications

      04/18/2025

      🔬 Immunotherapy in Pseudomyxoma Peritonei (PMP): Can We Overcome the Mucin Barrier?

      04/09/2025

      Understanding GNAS Mutations in Pseudomyxoma Peritonei: Molecular Insights and Clinical Implications

      04/09/2025

      Understanding the GNAS Mutation in Pseudomyxoma Peritonei: Molecular Insights, Mucin Regulation, and Therapeutic Implications

      04/18/2025

      🔬 Immunotherapy in Pseudomyxoma Peritonei (PMP): Can We Overcome the Mucin Barrier?

      04/09/2025

      Understanding GNAS Mutations in Pseudomyxoma Peritonei: Molecular Insights and Clinical Implications

      04/09/2025

      🔬 CHIPOR Trial: Does HIPEC Improve Survival in Recurrent Ovarian Cancer?

      04/06/2025
    • Journal
      1. ASO
      2. EJSO
      3. JSO
      4. Pleura & Peritoneo
      5. View All
    • Spiral of Knowledge
      1. Basics of PSM
      2. Translational Research PSM
      3. View All
    • About Us
    • Contact Us
    Subscribe to Our Newsletter
    Peritoneo.life
    Home»Blog»Carcinomatose Peritoneal: A Quantidade De Doença Faz Diferença? Entenda O Que É O PCI?
    Blog

    Carcinomatose Peritoneal: A Quantidade De Doença Faz Diferença? Entenda O Que É O PCI?

    Dr. Artur ReisBy Dr. Artur Reis02/27/2025Updated:03/17/2025No Comments2 Mins Read
    Facebook LinkedIn WhatsApp Twitter Email
    Share
    LinkedIn Facebook WhatsApp Twitter Email

    Quase todos os dias recebo perguntas de pessoas me perguntando sobre carcinomatose peritoneal…

    Aqui vou explicar de forma simples e clara um conceito básico que vai te ajudar a entender se a QUANTIDADE de Carcinomatose Peritoneal faz diferença no seu tratamento.

    Todo mundo que descobre uma doença peritoneal faz a pergunta:

    “Mas é muito pouco?”

    Uma maneira que os médicos encontraram de medir a quantidade de carcinomatose peritoneal é o Índice de Carcinomatose Peritoneal ou PCI (Peritoneal Carcinomatosis Index), do inglês.

    O PCI (índice de Carcinomatose Peritoneal) é a métrica que nos permite quantificar o volume de doença presente no peritoneo.1234

    Porque o PCI É Tão Importante?

    Ele tem se mostrado um fator prognóstico independente associado à sobrevida. Isto é, quanto menor é o PCI, melhor é a sobrevida encontrada nas séries de caso estudadas. 5

    Impacto do Indice de Carcinomatose Peritoneal na sobrevida global de pacientes selecionados submetidos a Peritonectomia + HIPEC por metastáse de Cancer Colorretal (P < 0.001). 6

    Além disso, o PCI prediz a PROBABILIDADE DE SUCESSO NA CITORREDUÇÃO COMPLETA, ou seja, pacientes com PCI BAIXO possuem uma probabilidade MAIOR de ressecção completa de todos os nódulos visíveis.

    Como O PCI É Calculado?

    O PCI foi originalmente criado para ser calculado no durante as Peritonectomias (durante a cirurgia mesmo), mas hoje existem outras formas de prever o PCI através de exames de imagem (tomografia (TC) ou ressonância (RNM)) ou através de videolaparoscopia.

    A variabilidade costuma ser pequena, mas vale lembrar que a TC ou a RNM conseguem detectar nódulos maiores de 0,5cm apenas.

    Portanto, os nódulos menores podem passar despercebidos.

    O cálculo é bem simples… dividimos o abdome em 13 regiões e atribuímos uma nota de 0 a 3 a cada região acometida, dependendo do tamanho dos nódulos encontrados em cada região. Figura 1

    Como Faço Para Saber O Meu PCI?

    A melhor maneira é ser avaliado por um médico com experiência em doenças peritoneais.

    São necessários muitos anos de estudo para entender como a doença se comporta e como prever a evolução dela.

    Se este assunto chamou a sua atenção e eu puder ajudar, entre em contato conosco pelo Whatsapp.

    Grande Abraço!

    Trending
    Share. Facebook LinkedIn WhatsApp Twitter Email Telegram Copy Link
    Dr. Artur Reis
    • Website

    Dr. Artur Reis– Specialist in Peritoneal Surface Oncology, certified by the European Society of Surgical Oncology (ESSO). With expertise in Cytoreductive Surgery with HIPEC and PIPAC, Dr. Reis is committed to advancing surgical oncology through research, education, and innovation. As the curator of P.life Papers, he bridges the gap between clinical practice and scientific knowledge, ensuring that oncology professionals have access to cutting-edge research and best practices. He is the Director of the Specialized Center for Peritoneal Surface Oncology at Santa Casa de São José dos Campos and the Director of the Peritoneal Oncology Center at Hospital Rede D'Or Vivalle. Registered medical doctor with the Brazilian Medical Council (CRM-SP: 124.285/ RQE:41.487).

    Related Posts

    🧠 P.life Papers – Science That Reaches Further

    By Dr. Artur Reis03/23/2025

    Revolutionizing Peritoneal Cancer Treatment: Key Studies Unveiled at ASCO 2023

    By Dr. Artur Reis03/06/2025
    Leave A Reply Cancel Reply

    Don't Miss
    Blog

    🧠 P.life Papers – Science That Reaches Further

    By Dr. Artur Reis03/23/20250

    Knowledge That Impacts Lives Beyond the Operating Room ✍️ By Dr. Artur Reis Specialist in…

    Revolutionizing Peritoneal Cancer Treatment: Key Studies Unveiled at ASCO 2023

    03/06/2025
    Follow us
    • Instagram
    • YouTube
    Latest Articles

    Understanding the GNAS Mutation in Pseudomyxoma Peritonei: Molecular Insights, Mucin Regulation, and Therapeutic Implications

    04/18/2025

    🔬 Immunotherapy in Pseudomyxoma Peritonei (PMP): Can We Overcome the Mucin Barrier?

    04/09/2025

    Understanding GNAS Mutations in Pseudomyxoma Peritonei: Molecular Insights and Clinical Implications

    04/09/2025

    🔬 CHIPOR Trial: Does HIPEC Improve Survival in Recurrent Ovarian Cancer?

    04/06/2025

    Subscribe to Our Newsletter

    Join our community of medical professionals and receive the latest expert insights, clinical updates, and breakthrough research on peritoneal surface malignancies.

    About
    About

    Explore the latest advancements in Peritoneal Surface Malignancies (PSM). This curated collection of research papers offers valuable insights, clinical findings, and surgical techniques. Stay informed about cutting-edge developments in PSM treatment and management, designed for PSM experts and physicians with a keen interest in this specialized field.

    Email Us: contato@peritoneo.life

    Latest Articles

    Understanding the GNAS Mutation in Pseudomyxoma Peritonei: Molecular Insights, Mucin Regulation, and Therapeutic Implications

    04/18/2025

    🔬 Immunotherapy in Pseudomyxoma Peritonei (PMP): Can We Overcome the Mucin Barrier?

    04/09/2025

    Understanding GNAS Mutations in Pseudomyxoma Peritonei: Molecular Insights and Clinical Implications

    04/09/2025

    Subscribe to Our Newsletter

    Join our community of medical professionals and receive the latest expert insights, clinical updates, and breakthrough research on peritoneal surface malignancies.

    Instagram YouTube
    • Home
    • Disease
    • Journal
    • Spiral of Knowledge
    • About Us
    • Contact Us
    • Privacy Policy
    © 2025 Peritoneo Life. Developed by Native Web Agência de Marketing.

    Type above and press Enter to search. Press Esc to cancel.

    pt Portugueseen Englishfr Frenchde Germanar Arabicja Japanesezh-CN Chinese (Simplified)zh-TW Chinese (Traditional)nl Dutchit Italianru Russianes Spanishuk Ukrainianth Thaipl Polishno Norwegianko Koreanel Greekhu Hungarianro Romaniansv Swedishga Irish
    en en